{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T08:35:03Z","timestamp":1790670903465,"version":"4.1.0"},"reference-count":38,"publisher":"Impact Journals, LLC","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2018,2,9]]},"DOI":"10.18632\/oncotarget.23919","type":"journal-article","created":{"date-parts":[[2018,1,4]],"date-time":"2018-01-04T16:10:06Z","timestamp":1515082206000},"page":"9766-9775","source":"Crossref","is-referenced-by-count":15,"title":["Evaluation of tenascin-C by tenatumomab in T-cell non-Hodgkin lymphomas identifies a new target for radioimmunotherapy"],"prefix":"10.18632","volume":"9","author":[{"given":"Giuseppe","family":"Gritti","sequence":"first","affiliation":[{"name":"Hematology Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Gianatti","sequence":"additional","affiliation":[{"name":"Pathology Unit, Ospedale Papa Giovanni XXII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorella","family":"Petronzelli","sequence":"additional","affiliation":[{"name":"Sigma Tau S.p.A. Biotech Products R and D, Pomezia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"De Santis","sequence":"additional","affiliation":[{"name":"Sigma Tau S.p.A. Biotech Products R and D, Pomezia, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Pavoni","sequence":"additional","affiliation":[{"name":"Hematology Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riccardo Lorenzo","family":"Rossi","sequence":"additional","affiliation":[{"name":"Bioinformatics, Istituto Nazionale Genetica Molecolare, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Cattaneo","sequence":"additional","affiliation":[{"name":"Pathology Unit, Ospedale Papa Giovanni XXII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi Giusto","family":"Spagnoli","sequence":"additional","affiliation":[{"name":"Department of Biomedicine and Prevention, Universit\u00e0 di Roma Tor Vergata, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Ferrari","sequence":"additional","affiliation":[{"name":"Hematology Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rossi","sequence":"additional","affiliation":[{"name":"Hematology Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Maria","family":"Barbui","sequence":"additional","affiliation":[{"name":"Hematology Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Rambaldi","sequence":"additional","affiliation":[{"name":"Hematology Unit, Ospedale Papa Giovanni XXIII, Bergamo, Italy"},{"name":"Department of Oncology and Oncohematology, Universit\u00e0 degli Studi di Milano, Milan, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2018,1,3]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"3462","DOI":"10.1158\/1078-0432.CCR-13-0855","article-title":"PD-L1 expression is characteristic of a subset of aggressive B-cell lymphomas and virus-associated malignancies","volume":"19","author":"Rodig","year":"2013","journal-title":"Clin Cancer Res"},{"key":"2","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrclinonc.2015.187","article-title":"Novel immunotherapies in lymphoid malignancies","volume":"13","author":"Younes","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"3","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1200\/JCO.2010.29.9024","article-title":"Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study","volume":"29","author":"Furman","year":"2011","journal-title":"J Clin Oncol"},{"key":"4","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1200\/JCO.2011.37.4223","article-title":"Results from a pivotal, open-label, phase II study of Romidepsin in relapsed or refractory peripheral T-cell lymphoma after prior systemic therapy","volume":"30","author":"Shustov","year":"2012","journal-title":"J Clin Oncol"},{"key":"5","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1200\/JCO.2011.38.0402","article-title":"Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study","volume":"30","author":"Kennedy","year":"2012","journal-title":"J Clin Oncol"},{"key":"6","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1200\/JCO.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal Phase II BELIEF (CLN-19) study","volume":"33","author":"Walewski","year":"2015","journal-title":"J Clin Oncol"},{"key":"7","volume-title":"Pathology and genetics of tumours of hematopoietic and lymphoid tissues. World Health Organization classification of tumours","author":"Vardiman","year":"2008"},{"key":"8","doi-asserted-by":"crossref","first-page":"4124","DOI":"10.1200\/JCO.2008.16.4558","article-title":"International peripheral T-cell and natural killer\/T-cell lymphoma study: pathology findings and clinical outcomes","volume":"26","author":"Weisenburger","year":"2008","journal-title":"J Clin Oncol"},{"key":"9","doi-asserted-by":"crossref","first-page":"e0121822","DOI":"10.1371\/journal.pone.0121822","article-title":"Primary treatment response rather than front line stem cell transplantation is crucial for long term outcome of peripheral T-cell lymphomas","volume":"10","author":"Rambaldi","year":"2015","journal-title":"PLoS One"},{"key":"10","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1582-4934.2011.01360.x","article-title":"How do tenascins influence the birth and life of a malignant cell?","volume":"16","author":"Chiquet-Ehrismann","year":"2012","journal-title":"J Cell Mol Med"},{"key":"11","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1016\/S0959-8049(98)00215-9","article-title":"Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion","volume":"34","author":"Virtanen","year":"1998","journal-title":"Eur J Cancer"},{"key":"12","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1247\/csf.26.179","article-title":"Tenascin-C splice variant adhesive\/anti-adhesive effects on chondrosarcoma cell attachment to fibronectin","volume":"26","author":"Scully","year":"2001","journal-title":"Cell Struct Funct"},{"key":"13","first-page":"301","article-title":"Angiogenesis in the central nervous system: a role for vascular endothelial growth factor\/vascular permeability factor and tenascin-C. Common molecular effectors in cerebral neoplastic and non-neoplastic \u201cangiogenic diseases\u201d","volume":"17","author":"Capo","year":"2002","journal-title":"Histol Histopathol"},{"key":"14","doi-asserted-by":"crossref","first-page":"6431","DOI":"10.4049\/jimmunol.167.11.6431","article-title":"The alternatively spliced domain TnFnIII A1A2 of the extracellular matrix protein tenascin-C suppresses activation-induced T lymphocyte proliferation and cytokine production","volume":"167","author":"Ruegg","year":"2001","journal-title":"J Immunol"},{"key":"15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1365-2559.1995.tb00640.x","article-title":"Distribution of extracellular matrix components and their receptors in human lymphoid tissue and B-cell non-Hodgkin lymphomas","volume":"26","author":"Meijer","year":"1995","journal-title":"Histopathology"},{"key":"16","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3109\/10428199609054786","article-title":"Expression of tenascin is related to histologic malignancy and angiogenesis in b-cell non-Hodgkin's lymphomas","volume":"22","author":"Dammacco","year":"1996","journal-title":"Leuk Lymphoma"},{"key":"17","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/j.leukres.2009.06.025","article-title":"Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma","volume":"33","author":"Neri","year":"2009","journal-title":"Leuk Res"},{"key":"18","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1080\/10428190500158060","article-title":"Tenascin and microvessel stromal changes in patients with non-Hodgkin's lymphoma are isolated to the sites of disease and vary in correlation to disease activity","volume":"46","author":"Bigner","year":"2005","journal-title":"Leuk Lymphoma"},{"key":"19","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1007\/s002590050397","article-title":"Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin","volume":"26","author":"Veronesi","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"20","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s00259-013-2658-6","article-title":"Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma","volume":"41","author":"Lastoria","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"21","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1182\/blood-2003-12-4264","article-title":"Phase 1 trial study of 131I-labeled chimeric 81C6 monoclonal antibody for the treatment of patients with non-Hodgkin lymphoma","volume":"104","author":"Gockerman","year":"2004","journal-title":"Blood"},{"key":"22","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1038\/sj.bjc.6600818","article-title":"Novel antitenascin antibody with increased tumour localisation for Pretargeted Antibody-Guided RadioImmunoTherapy (PAGRIT)","volume":"88","author":"Campanile","year":"2003","journal-title":"Br J Cancer"},{"key":"23","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1158\/1078-0432.CCR-05-2526","article-title":"Low and high tenascin-expressing tumors are efficiently targeted by ST2146 monoclonal antibody","volume":"12","author":"Cassani","year":"2006","journal-title":"Clin Cancer Res"},{"key":"24","doi-asserted-by":"crossref","first-page":"7137s","DOI":"10.1158\/1078-0432.CCR-1004-0007","article-title":"Improved tumor targeting by combined use of two antitenascin antibodies","volume":"11","author":"De Santis","year":"2005","journal-title":"Clin Cancer Res"},{"key":"25","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","article-title":"Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma","volume":"115","author":"Delabie","year":"2010","journal-title":"Blood"},{"key":"26","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1172\/JCI26833","article-title":"Gene expression analysis of peripheral T cell lymphoma, unspecified, reveals distinct profiles and new potential therapeutic targets","volume":"117","author":"Pileri","year":"2007","journal-title":"J Clin Invest"},{"key":"27","doi-asserted-by":"crossref","first-page":"5240","DOI":"10.1158\/1078-0432.CCR-14-2020","article-title":"Changing the paradigms of treatment in peripheral T-cell lymphoma: from biology to clinical practice","volume":"20","author":"Bates","year":"2014","journal-title":"Clin Cancer Res"},{"key":"28","doi-asserted-by":"crossref","first-page":"e106745","DOI":"10.1371\/journal.pone.0106745","article-title":"Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival","volume":"9","author":"Rambaldi","year":"2014","journal-title":"PLoS One"},{"key":"29","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Oki","year":"2014","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"996","DOI":"10.3324\/haematol.2010.037408","article-title":"High microvessel density determines a poor outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus chemotherapy","volume":"96","author":"Gascoyne","year":"2011","journal-title":"Haematologica"},{"key":"31","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1182\/blood-2010-02-270785","article-title":"Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group","volume":"116","author":"Pfreundschuh","year":"2010","journal-title":"Blood"},{"key":"32","first-page":"1035","article-title":"Tenascin expression in cancer cells and stroma of human breast cancer and its prognostic significance","volume":"1","author":"Sakakura","year":"1995","journal-title":"Clin Cancer Res"},{"key":"33","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1097\/01.MP.0000086860.65672.73","article-title":"Tenascin expression at the invasive front is associated with poor prognosis in intrahepatic cholangiocarcinoma","volume":"16","author":"Tsuneyoshi","year":"2003","journal-title":"Mod Pathol"},{"key":"34","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1007\/s004280050433","article-title":"Involvement of tenascin-C in proliferation and migration of laryngeal carcinoma cells","volume":"435","author":"Sakakura","year":"1999","journal-title":"Virchows Arch"},{"key":"35","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1111\/j.1349-7006.1992.tb02724.x","article-title":"Human carcinoma cells synthesize and secrete tenascin","volume":"83","author":"Sakakura","year":"1992","journal-title":"Jpn J Cancer Res"},{"key":"36","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1600-0609.2007.00910.x","article-title":"Pretargeted antibody-guided radioimmunotherapy in a child affected by resistant anaplastic large cell lymphoma","volume":"79","author":"Paganelli","year":"2007","journal-title":"Eur J Haematol"},{"key":"37","doi-asserted-by":"crossref","first-page":"907","DOI":"10.5858\/134.6.907","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"134","author":"Love","year":"2010","journal-title":"Arch Pathol Lab Med"},{"key":"38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1080\/19336918.2015.1005452","article-title":"Spatial organization of the tenascin-C microenvironment in experimental and human cancer","volume":"9","author":"Slotta-Huspenina","year":"2015","journal-title":"Cell Adh Migr"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23919","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T20:42:51Z","timestamp":1660250571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.23919"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,3]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,2,9]]}},"alternative-id":["23919","29515769"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.23919","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,3]]}}}